Drug resistance mutations and their influencing factors in the patients infected with HIV-1 through different routes after antiretroviral therapy

• Published in: Jie fang jun yi xue za zhi Vol. 40; no. 7; p. 591
• Main Authors: Xin-li, LU, Xian-jiang, KANG, Hong-ru, ZHAO, Cui-ying, ZHAO, WANG, Wei, Guang-yi BAI, LI, Yan, Su-liang, CHEN
• Format: Journal Article
• Language: Chinese
• Published: Beijing People's Military Medical Press 25.07.2015
• Subjects: Antiretroviral drugs; Drug resistance; Mutation; Protease inhibitors
• ISSN: 0577-7402
• DOI: 10.11855/j.issn.0577-7402.2015.07.16

Objective　To analyze HIV-1 drug resistance mutations and relative factors in the patients infected with HIV-1 through different routes after having received highly active anti-retroviral therapy (HAART) in Hebei province. Methods　Plasma samples were collected from patients who were infected with HIV through different routes. Detection of HIV-1 RNA pol region was carried out by detection of genotype, and HIV drug resistance mutations were analyzed. Results　Among 266 patients, 157 developed mutation. The rate of the drug-resistance was 59.0%. Among 266 patients, drug-resistance rates were ranked from high to low as follows: NVP 65.8% (175/266), 3TC 41.7% (111/266), FTC 41.7% (111/266), EFV 30.1% (80/266), DDI 5.6% (15/266), D4T 4.1% (11/266), AZT 3.0% (8/266) and ABC 3.0% (8/266). The drug-resistance rate of blood infection patients was much higher than that of sexual and mother-to-child transmission ones, but χ2-test indicated that the differences in main mutation sites (Y181C, K103N, V108I, K101E in NNRTIS co